Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, metformin, sitagliptin, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 18
States / cities: Buena Park, California • Los Angeles, California • Valencia, California + 15 more

Conditions: Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD)
Interventions: Zeleciment Rostudirsen (DYNE-251), Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 4 Years to 18 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Hillsborough, North Carolina

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Rivoglitazone; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 70
States / cities: Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 67 more

Conditions: Inflammation
Interventions: Difluprednate, Placebo; Drug · Other
Lead sponsor: Sirion Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Celiac Disease
Interventions: PTG-100, Placebo; Drug
Lead sponsor: Nielsen Fernandez-Becker; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Social Anxiety Disorder
Interventions: Cannabidiol oral solution, Placebo; Drug
Lead sponsor: EmpowerPharm Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 17
States / cities: Encino, California • Lemon Grove, California • Los Alamitos, California + 14 more

Conditions: Alzheimer's Disease
Interventions: ST101, Placebo; Drug
Lead sponsor: Sonexa Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 27
States / cities: Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more

Conditions: Presbyphonia
Interventions: Creatine monohydrate, Placebo; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 65 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Herpes Simplex
Interventions: GSK208141, Havrix (investigational formulation), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 5,960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 66
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 54 more

Conditions: Multiple Sclerosis, Fatigue
Interventions: High Dose Aspirin (1300 mg/day), Low Dose Aspirin (162 mg/day), Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: CPPD - Calcium Pyrophosphate Deposition Disease
Interventions: Colchicine Pill, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 1 more

Conditions: Obesity or Overweight
Interventions: RO7795081, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 36
States / cities: Anniston, Alabama • Lake Forest, California • Rancho Cucamonga, California + 31 more

Conditions: RSV Infection
Interventions: EDP-938, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 31
States / cities: Tempe, Arizona • Fresno, California • Lomita, California + 26 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Taletrectinib, Placebo; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more

Conditions: Endometriosis
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Allergic Rhinitis
Interventions: Grass MATA MPL 10200, Grass MATA MPL 18200, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Neptune City, New Jersey • Newark, New Jersey

Conditions: Acute Pain
Interventions: VX-150, HB/APAP, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 4
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, California + 1 more

Conditions: Sleep Disorders, Congestion, Nasal
Interventions: Prototype Nasal Dilator, Marketed Nasal Strip, Placebo Nasal Strip; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Paramus, New Jersey • Bethlehem, Pennsylvania

Conditions: Allergic Rhinitis, Allergic Conjunctivitis
Interventions: olopatadine, placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hot Flashes
Interventions: Fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 65
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Depression
Interventions: Risperidone and placebo comparator; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pain, Anxiety
Interventions: Placebo Group, Buddhify Therapy; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer Recurrent
Interventions: Ombrabulin (AVE8062), Placebo, Paclitaxel, Carboplatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Burbank, California • New Haven, Connecticut • Fort Meyers, Florida + 2 more

Search by objective public record fields.

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

Study of Rivoglitazone in Type 2 Diabetes Mellitus

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

PTG-100 for Patients With Celiac Disease

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

Creatine Supplementation for Improved Voice Performance in the Elderly

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis

A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Exploratory Subjective Sleep Study of a Prototype Nasal Dilator

Olopatadine Eye Drops and Allergy Skin Testing

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

Risperidone and Suicidality in Major Depressive Disorder

A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures.

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel